Clinical Trial: Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency

This study has been completed.

Sponsors and Collaborators: National Center for Research Resources (NCRR)
University of California, Los Angeles
Information provided by: Office of Rare Diseases (ORD)


OBJECTIVES: I. Determine the efficacy of dehydroepiandrosterone (DHEA), an androgen replacement hormone, for patients with primary adrenal insufficiency (Addison's disease).

Condition Treatment or Intervention Phase
Addison's Disease
 Drug: dehydroepiandrosterone
Phase III

MedlinePlus related topics:  Addison's Disease

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Efficacy Study

Further Study Details: 

Expected Total Enrollment:  40

Study start: August 1995

PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are stratified by age. Patients are randomly assigned to androgen replacement therapy with daily dehydroepiandrosterone (DHEA) or placebo for 6 months. All patients may receive 6 additional months of DHEA following randomized therapy. Women on hormonal replacement therapy may receive concurrent conjugated estrogens or oral medroxyprogesterone.


Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both


PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Primary adrenal insufficiency (Addison's disease) Serum dehydroepiandrosterone less than 0.5 nmol/L --Prior/Concurrent Therapy-- No concurrent investigational drug Stable glucocorticoid/mineralocorticoid dose over past year required --Patient Characteristics-- Hepatic: No hepatic disease Cardiovascular: No vascular disease No thrombotic disorder No angina No elevated blood pressure on 2 readings taken 15 minutes apart in 1 visit, i.e.: Systolic greater than 165 mm Hg OR Diastolic greater than 95 mm Hg Other: No clinically significant medical abnormality No gallbladder disease No malignancy No estrogen- or androgen-dependent neoplasia Benign prostatic hyperplasia eligible No other endocrine disease Controlled thyroid disease with normal thyroid-stimulating hormone eligible Mammogram required within 1 year prior to entry for women aged 40 and over No clinically significant abnormality No undiagnosed vaginal or uterine bleeding within 6 months prior to entry Pap smear required within 1 year prior to entry No dysplasia (squamous intraepithelial lesion low-grade or higher)

Location Information

Study chairs or principal investigators

Samuel S. C. Yen,  Study Chair,  University of California, Los Angeles   

More Information

Study ID Numbers:  199/11822; UCSD-1062
Record last reviewed:  January 2000
Last Updated:  October 13, 2004
Record first received:  October 18, 1999 Identifier:  NCT00004313
Health Authority: United States: Federal Government processed this record on 2005-04-08

Cache Date: April 9, 2005